Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 27, 2026 10:40 ET | Source: Artelo Biosciences SOLANA BEACH, Calif.,…
Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE Cell-Therapy Platform Toward First-in-Human Study
Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study…
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
-- Issues Statement in Response to DOMA’s Nomination of Director Candidates --…
CORRECTING & REPLACING — MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3…
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
February 28, 2026 09:45 ET | Source: Cogent Biosciences, Inc. Bezuclastinib mean…
Lifespan Vision Ventures Co-Leads Sift Biosciences’ $3.7M Pre-Seed Financing
NORWALK, Conn., Feb. 18, 2026 /PRNewswire/ -- Lifespan Vision Ventures, an investment…
Waters Completes Combination with BD’s Biosciences & Diagnostic Solutions Businesses
Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms…
Alamar Biosciences Announces Launch of NULISAqpcr AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a…
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investorsStephen…
LIfT BioSciences Announces CEO Transition to Drive Next Phase of Growth with Neutrophil-based Therapies
Dr. Bo Rode Hansen, current Board member and Corporate Development Officer named…
